JimmyBOY what experience is that? There were 29 biotech

New Post Public Reply Private Reply Replies (4) Message Board

Nov 20, 2018 at 12:51 PM 1,020

JimmyBOY what experience is that? There were 29 biotech buyouts or mergers just in Nov/Dec/ 2017!!!!! Stop with your BULLSHIT!!!!
Did you know Glaxo and Smithkline MERGED on 12/31/2000?

Company Takeover candidate Deal Value $ Completed
3SBio (China) Therapure Biopharma (Canada) biomanufacturing business $290 million Dec 2017

Alembic
Pharmaceuticals
(India) Orit Laboratories (US) Undisclosed Nov 2017

Altimmune (US) PharmAthene (US) Undisclosed May 2017

Alvogen (US) Omega Bittner (Russia), from Perrigo (US) Undisclosed Oct 2017

Amneal (US) Impax Laboratories (US) Undisclosed all-stock merger Dec 2017

Arcturus Therapeutics (US) Alcobra (Israel) Reverse merger valued at $46.7 million Nov 2017

Astellas Pharma (Japan) Ogeda (Belgium) $856 million Nov 2017

Astellas Pharma (Japan) Mitobridge (US) $450 million of which $225 million upfront Dec 2017

Aurora Cannabis (Canada) Peloton Pharmaceuticals (Canada) $7 million Apr 2017

Bain Capital and Cinven consortium Stada Arzneimittel $4.36 billion Deal resurrected after being dropped on lack of shareholder support late June 2017; closed in Sept 2017

BioLineRx (Israel) Agalimmune (UK) $6 million 50:50 cash and shares deal Mar 2017

Biotoscana, Grupo (Uruguay) Laboratorio DOSA (Argentina) $30 million Nov 2017

Bioverativ (US) True North Therapeutics (US) $825 million of which $400 million upfront June 2017

Bristol-Myers Squibb (US) IFM Therapeutics (US) $300 million upfront and up to $2 billion in milestones Sept 2017

Carlyle Group and Pacific Equity Partners (US) iNova unit of Valeant Pharmaceuticals (Canada) $930 million Sept 2017

Carlyle and GCTR (US) Albany Molecular Research (US) $922 million Aug 2017

Catalent (US) Cook Pharmica (US) $950 million Oct 2017

Celgene (US) Delinia (US) $300 million upfront with $475 million contingent May 2017

Cell Medica (UK) Catapult Therapy TCR Undisclosed June 2017

Chengdu Kanghong Pharma (China) IOPtima from BioLight (Israel) $23-27 million to complete in stages Nov 2017

Clinigen Group (UK) Quantum Pharma (UK) $190 million Nov 2017

Collidion (US) Plex Pharmaceuticals (US) Undisclosed sum for 80% Aug 2017

CSL Limited (Australia) Wuhan Zhong Yuan Rui De Biological Products Wuhan Zhong Yuan Rui De Biological Products Aug 2017

CSL Limited (Australia) Calimmune (US) $91 million upfront and $325 million contingent Sept 2017

Creat Group Corp (China) Biotest (Germany) $1.3 billion Offer withdrawn in Nov 2017

CVS Health (US) Aetna (US) $69 billion Exp. 2nd half-2018
Ethypharm (France) Martindale Pharma (UK) Merger, value undisclosed Jan 2017

Evotec (Germany) Aptuit (USA) $300 million Aug 2017

Fosun Pharmaceutical (China) Tridem (France) $73 million Nov 2017

Fresenius Kabi (Germany) Akorn (US) $4.3 billion Exp. early 2018
Fresenius Kabi (Germany) Biosimilars business of Merck KGaA (Germany) $730 million Sept 2017

FujiFilm (Japan) EdiGene (Japan) $4 million for 11.7% equity stake Dec 2017

GenScript Biotech (Hong Kong) CustomArray (US) Undiclosed Exp.early 2018
Gilead Sciences (US) Kite Pharma (US) $11.9 billion Oct 2017

Gilead Sciences (US) Cell Design Labs (US) $175 million upfront, $322 million contingent Dec 2017

GL Capital-led consortium of Chinese investors SciClone Pharmaceutical (US) $605 million Oct 2017

Grifols (Spain) GigaGen (US) $35 million for 43.96% equity stake July 2017

Gurnet Point Capital (US) Innocoll Holdings (Ireland) $209 million July 2017

Haitong International Zhongua Finance (Hong Kong) Obagi Medical Products from Valeant Pharmaceutical (Canada) $190 million Nov 2017

Heat Biologics (US) Pelican Therapeutics (US) $1.5 million Apr 2017

Horizon Pharma (Ireland) River Vision Development (US) $145 million plus contingent payments May 2017

ImmunoPrecise (Canada) Preclinics (Germany) $2.7 million plus $895,500 contingent Early 2018
Kitov Pharmaceuticals (Israel) TyrNovo (Israel) $3.8 million ($2 million cash) for initial 56% equity stake. Acquired additional 27% stake for $7 million in shares Oct 2017

Eli Lilly (US) CoLucid (US) $960 million Mar 2017

Intrexon (US) GenVec (US) Undisclosed, all share transaction June 2017

Invent Farma/neuraxpharm (Spain) FB Health (Italy) Undisclosed June 2017

Johnson & Johnson (US) Actelion (Switzerland) $30 billion with spin-out of early-stage R&D Jan 2017

JSR Life Sciences (Japan) Selexis (Switzerland) Undisclosed June 2017

JSR Life Sciences (Japan) Crown Bioscience International (US) $400 million Ann. Dec 2017

Ligand Pharmaceuticals (US) Crystal Biosciences (US) $25 million plus $10.5 million contingent Dec 2017

Lupin (India) Symbiomix Therapeutics (US) $150 million, $50 million upfront Oct 2017

Mallinckrodt (US) InfaCare (US) $80 million upfront and $345 million contingent Dec 2017

Mallinckrodt (US) Ocera Therapeutics (US) $42 million plus up to $75 million contingent Dec 2017

Mallinckrodt (US) Sucampo Pharmaceuticals (US) $1.2 billion Exp. 1st-qtr 2018
Medicure (Canada) Apicore (US) $24.5 million for additional 32% equity stake July 2017

Melinta Therapeutics (US) Infectious disease business of The Medicines Company $270 million upfront plus $215 million contingent Exp. 1st-qtr 2018
Mercachem (Netherlands) Syncom (Netherlands) Undisclosed, merger of CROs Aug 2017

Merck & Co (US) Rigonetic (Germany) $600 million of which $137 million upfront Nov 2017

Millendo Therapeutics (US) Alizé Pharma SAS (France) Undisclosed stock transaction Dec 2017

Mitsubishi Tanabe Pharma (Japan) NeuroDerm (Israel) $1.1 billion Oct 2017
Molecular Templates (US) Threshold Pharmaceuticals (US) All-stock merger Aug 2017

Norgine (Netherlands) Merus Labs International (Canada) $342 million July 2017

Onzima Ventures (UK) N4 Pharma (UK) 51% not already owned; share deal Apr 2017

Otsuka Pharmaceutical (Japan) Neurovance (US) $100 million upfront and $150 million contingent June 2017

Pamplona Capital Management Parexel (US) $5 billion Sept 2017

PDL Biopharma (US) Neos Therapeutics (US) Unsolicited takeover offer of ~$287.8 million Rejected by Neos in Oct 2017

Quotient Sciences (UK) Pharmaterials (UK) Undisclosed Nov 2017

Regenxbio (US) Dimension Therapeutics (US) $86 million (later counter bid by Ultragenyx) Not consummated
Repligen (US) Spectrum Inc (US) $359 million, of which $120 million in cash Aug 2017

Roche (Switzerland) ForSight Vision4 (US) Undisclosed Jan 2017

Roche (Switzerland) Ignyta (US) $1.7 billion Exp. 1st-half 2018
Roquette (France) Itacel (Brazil) Undisclosed Sept 2017

Rostec (Russia) Marathon Group (Russia) Undisclosed merger Dec 2017

Sapphire (HK) Holdings (China) Hisun-Pfizer Pharma (US) Undisclosed, 49% stake from Pfizer Nov 2017

Sawai Pharmaceuticals (Japan) Generics business of Upsher-Smith (US) $1.05 billion June 2017

Sanofi (France) Protein Sciences (US) $650 million plus $100 million contingent Aug 2017

Savara (US) Mast Therapeutics (US) Undisclosed with a transaction value of around $150 million Exp. 2nd-qtr 2017

Sanpower (China) Dendreon (US) from Valeant Pharma (US) $819.9million June 2017

Sellas Life Sciences (Swiss/Greek) Galena Biopharma (US) Undisclosed, all stock merger Dec 2017

Sevion Therapeutics (US) Eloxx Pharmaceuticals (Israel) Undisclosed share deal Nov 2017

Sihuan Pharma (China) Ambest Pharmaceutical (China) $160 million Ann. Mar 2017

Silence Therapeutics (UK) Arrowhead Pharmaceuticals (US) $9.6 million for 8.4% equity stake Jan 2017

SK Capital (US) Perrigo API, the ingredients unit of Perrigo (Ireland) $110 million Nov 2017

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Icebox Takes on Buckhead with Diamonds and Discounts

So, Atlanta's Icebox Diamonds & Watches just dropped a news bomb that could shake up anyone with a taste for glitz and a wallet ready to act. This iconic jeweler, swinging its roots from a humble family biz to a global gem, is opening up its vault with an Inventory Reduction Sale starting October 9. And folks, it’s happening right at their Buckhead flagship showroom....

Webull Faces Legal Scrutiny Over Chinese Ties

The Unfolding Drama for Webull Shareholders When you see a ticker like NASDAQ:BULL rolling off your tongue these days, it’s not just about stock prices anymore—it's a whole saga wrapped in legal and geopolitical spice. Following the recent uproar from a House China committee report, Webull found itself thrust into the spotlight for all the wrong reasons. That report...

Aspen Dental Brings Comprehensive Care to Whiteville

Bringing Dentistry Closer to Home Now, Whiteville's dental game just got a power-up, with Aspen Dental setting up shop in town. This isn't just another practice popping up—it's a full-on dental hub offering everything from regular cleanings to emergency tooth fixes. And let’s face it, this area's diverse population needs it. The Man Behind the Chair Guess who’s at...

Ardelyx Securities Fraud Suit: Key Investor Moves

Fraud Allegations: Ardelyx Under the Microscope Looks like Ardelyx has found itself neck-deep in trouble, facing a class action lawsuit over alleged securities fraud. This isn't just a storm in a teacup. We're talking about accusations of false and misleading statements tied to their commercial performance—statements that might have left investors holding the bag with...

Helio Genomics Shakes Up Liver Cancer Detection Strategy

Rethinking Liver Cancer Detection with HelioLiver Sometimes you stumble upon a tech piece that might genuinely shake up the game. Helio Genomics just poured some serious intel at the San Antonio Liver Cancer Symposium, showcasing how their HelioLiver Dx might outgun traditional scans in sniffing out hepatocellular carcinoma (HCC). They threw down four studies revealing...

Boliden's Q3 2026 Results: What's on the Horizon?

Boliden Ready to Reveal Q3 Numbers Mark it down, folks. Thursday, October 29, 2026, is the day when Boliden's big wigs will step up to the plate and lay their cards on the table about the company's performance over the last quarter. If you've got any skin in this mining powerhouse, you'll want a front-row seat—or at least a virtual one if you're dialing in from...

Raken Debuts Change Orders: A Game-Changer for Builds

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

PrideStaff: 8 Years Strong on Franchise Times Top 400

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Hexaware Teams with Anthropic for Game-Changing AI Move

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...

Full Sail University Bags Billboard Music School Honor

Full Sail Scores a Billboard Nod — What's the Big Deal? Alright, Full Sail University just snagged a spot on Billboard Magazine's 2026 Top Music Business Schools list. That's no small fry, folks. This Florida institution has been carving out a niche in the music business education scene with a hands-on learning approach that hits the nail right on the head. The Recipe...